D. E. Shaw & Co., Inc. Werewolf Therapeutics, Inc. Transaction History
D. E. Shaw & Co., Inc.
- $122 Billion
- Q4 2024
A detailed history of D. E. Shaw & Co., Inc. transactions in Werewolf Therapeutics, Inc. stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 17,776 shares of HOWL stock, worth $25,775. This represents 0.0% of its overall portfolio holdings.
Number of Shares
17,776Holding current value
$25,775% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding HOWL
# of Institutions
73Shares Held
28MCall Options Held
12KPut Options Held
14K-
Ra Capital Management, L.P. Boston, MA6.14MShares$8.91 Million0.15% of portfolio
-
Mpm Asset Management LLC Cambridge, MA4.28MShares$6.21 Million5.1% of portfolio
-
Pfm Health Sciences, LP San Francisco, CA2.91MShares$4.21 Million0.28% of portfolio
-
Bio Impact Capital LLC Cambridge, MA2.39MShares$3.46 Million0.53% of portfolio
-
Bank Of America Corp Charlotte, NC2.08MShares$3.01 Million0.0% of portfolio
About Werewolf Therapeutics, Inc.
- Ticker HOWL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 29,529,400
- Market Cap $42.8M
- Description
- Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional ...